Cytokines and serotonin transporter in patients with major depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 5, 2006, Pages 899-905

  Tsao, Chiung Wen ^a   Lin, Yee Shin ^b   Chen, Chwen Cheng ^b,c   Bai, Chyi Huey ^d   Wu, Shin Rung ^b  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c PFIZER   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Cytokines; Major depression; Serotonin transporter

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; FLUOXETINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DNA PRIMERS; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 33646904326     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.01.029     Document Type: Article

References (66)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Fourth ed. (1994), American Psychiatric Press, Washington, DC
2. Anisman H., and Merali Z. Cytokines, stress, and depressive illness. Brain Behav Immun 16 (2002) 513-524
3. Bauer J., Hohagen F., Gimmel E., Bruns F., Lis S., Krieger S., et al. Induction of cytokine synthesis and fever suppresses REM sleep and improves mood inpatients with major depression. Biol Psychiatry 38 (1995) 611-621
4. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15 (1994) 220-226
5. Brambilla F., Monteleone P., and Maj M. Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J Affect Disord 78 (2004) 273-277
6. Capuron L., and Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 17 Suppl. 1 (2003) S119-S124
7. Capuron L., Ravaud A., Neveu P., Miller A.H., Maes M., and Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiat 7 (2002) 468-473
8. Castanon N., Bluthe R.M., and Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology 154 (2001) 50-60
9. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 59 Suppl. 14 (1998) S11-S14
10. Connor T.J., and Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62 (1998) 583-606
11. Connor T.J., Harkin A., Kelly J.P., and Leonard B.E. Olfactory bulbectomy provokes a suppression of interleukin-1β and tumour necrosis factor-α production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation 7 (2000) 27-35
12. Dang Y., Dale W.E., and Brown O.R. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med 28 (2000) 615-624
13. de Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behav Immun 16 (2002) 610-617
14. Faraj B.A., Olkowski Z.L., and Jackson R.T. Expression of a high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol 16 (1994) 561-567
15. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., and Berger M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247 (1997) 228-233
16. Gladkevich A., Kauffman H.F., and Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 559-576
17. Guillemin G.J., Kerr S.J., Pemberton L.A., Smith D.G., Smythe G.A., Armati P.J., et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res 21 (2001) 1097-1101
18. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33 (1999) 407-418
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
20. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., and Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 19 (2003) 183-188
21. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
22. Irwin M., Lacher U., and Caldwell C. Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects. Psychol Med 22 (1992) 1045-1050
23. Jozuka H., Jozuka E., Takeuchi S., and Nishikaze O. Comparison of immunological and endocrinological markers associated with major depression. J Int Med Res 31 (2003) 36-41
24. Kenis G., and Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 5 (2002) 401-412
25. Kronfol Z., and House J.D. Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 80 (1989) 142-147
26. Kubera M., Kenis G., Bosmans E., Zieba A., Dudek D., Nowak G., et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol 52 (2000) 237-241
27. Kubera M., Kenis G., Bosmans E., Kajta M., Basta-Kaim A., Scharpe S., et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 4 (2004) 185-192
28. Lesch K.P., Bengel D., Helis A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
29. Lima L., and Urbina M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol Neurobiol 22 (2002) 797-804
30. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461 (1999) 25-46
31. Maes M., Lambrechts J., Suy B., Vandervorst C., and Bosmans E. Absolute number and percentage of circulating natural killer, non-MNC-restricted T cytotoxic, and phagocytic cells in unipolar depression. Neuropsychobiology 29 (1994) 157-163
32. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., et al. Treatment with interferon-α (IFNα) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNα-induced depressive and anxiety symptoms and immune activation. Mol Psychiat 6 (2001) 475-480
33. Merali Z., Lacosta S., and Anisman H. Effect of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission-a regional microdialysis study. Brain Res 761 (1997) 225-235
34. Marazziti D., Rossi A., Giannaccini G., Baroni S., Lucacchini A., and Cassano G.B. Presence and characterization of the serotonin transporter in human resting lymphocytes. Neuropsychopharmacology 19 (1998) 154-159
35. Mellerup E.T., and Plenge P. Impramine binding in depression and other psychiatric conditions. Acta Psychiatr Scand Suppl. 78 (1988) S61-S68
36. Meltzer H.Y., and Arora R.C. Genetic control of serotonin uptake in blood platelets: a twin study. Psychiatry Res 24 (1988) 263-269
37. Meltzer H.Y., Arora R.C., Baber R., and Tricou B.J. Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry 38 (1981) 1322-1326
38. Miller A.H., Pariante C.M., and Pierce B.D. Effects of cytokines on glucocorticoid receptor expression and function: glucocorticoid resistance and relevance to depression. In: Dantzer R., Wollman E., and Yirmiya R. (Eds). Cytokines, stress, and depression (1999), Plenum/Kluwer Academic Publishers, New York 107-116
39. Morikawa O., Sakai N., Obara H., and Saito N. Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349 (1998) 317-324
40. Mossner R., Heils A., Stober G., Okladnova O., Daniel S., and Lesch K.P. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not interleukin-6. Neurochem Int 33 (1998) 251-254
41. Mossner R., Daniel S., Schmitt A., Albert D., and Lesch K.P. Modulation of serotonin transporter function by interleukin-4. Life Sci 68 (2001) 873-880
42. Myint A.M., and Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61 (2003) 519-525
43. O'Brien S.M., Scott L.V., and Dinan T.G. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19 (2004) 397-403
44. O'Neill B., and Leonard B.E. Abnormal zymosan-induced neutrophil chemiluminescence as a marker of depression. J Affect Disord 19 (1990) 265-272
45. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49 (2001) 391-404
46. Paul S.M., Rehavi M., Skolnick P., Ballenger J.C., and Goodwin F.K. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry 38 (1981) 1315-1317
47. Purselle D.C., and Nemeroff C.B. Serotonin transporter: a potential substrate in the biology of suicide. Neuropsychopharmacology 28 (2003) 613-619
48. Ramamoorthy S., Bauman A.L., Moore K.R., Han H., Yang-Feng T., Chang A.S., et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A 90 (1993) 2542-2546
49. Ramamoorthy S., Ramamoorthy J.D., Prasad P.D., Bhat G.K., Mahesh V.B., Leibach F.H., et al. Regulation of the human serotonin transporter by interleukin-1. Biochem Biophys Res Commun 216 (1995) 560-567
50. Sakash J.B., Byrne G.I., Lichtman A., and Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun 70 (2002) 3959-3961
51. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 201-217
52. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., and Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 41 (1995) 534-538
53. Sluzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., and Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 762 (1995) 474-476
54. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., et al. Indicators of immune activation in major depression. Psychiatry Res 64 (1996) 161-167
55. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 49 (1998) 211-219
56. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51 (1998) 215-235
57. Steptoe A., Kunz-Ebrecht S.R., and Owen N. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol Med 33 (2003) 667-674
58. Suarez E.C., Krishnan R.R., and Lewis J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 65 (2003) 362-368
59. Syvalahti E.K. Biological aspects of depression. Acta Psychiatr Scand Suppl. 377 (1994) S11-S15
60. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., and O'Brien J.T. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162 (2005) 175-177
61. Trzonkowski P., Mysliwska J., Godlewska B., Szmit E., Lukaszuk K., Wieckiewicz J., et al. Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav Immun 18 (2004) 135-148
62. Tuglu C., Kara S.H., Caliyurt O., Vardar E., and Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170 (2003) 429-433
63. Tuomisto J., and Tukiainen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 262 (1976) 596-598
64. 3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine. Int J Immunopharmacol 21 (1999) 631-646
65. Weizman R., Laor N., Podliszewski E., Notti I., Djaldetti M., and Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 35 (1994) 42-47
66. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 24 (2001) 531-544